Adial Pharmaceuticals (ADIL) Amortizatization of Intangibles (2017 - 2023)
Adial Pharmaceuticals (ADIL) posted Amortizatization of Intangibles of $13768.0 for Q1 2023, up 2.18% sequentially from $13474.0 in Q4 2022, and up 8.93% YoY from $12639.0 in Q1 2022.
Adial Pharmaceuticals (ADIL) Amortizatization of Intangibles (2017 - 2023) Analysis & Trends
Adial Pharmaceuticals has reported Amortizatization of Intangibles for 5 years, with the latest figure at $13768.0 in Q1 2023.
- Quarterly Amortizatization of Intangibles rose 8.93% year-over-year to $13768.0 in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $53341.0 (up 8.72% YoY) and the FY2022 annual result came in at $52212.0, up 8.58% from the prior year.
- Amortizatization of Intangibles advanced to $13768.0 in Q1 2023 per ADIL's latest filing, from $13474.0 in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $13768.0 in Q1 2023 and troughed at $11663.0 in Q1 2021.
- A 3-year average of $12673.9 and a median of $12639.0 in 2022 frame the typical range for Amortizatization of Intangibles.
- The sharpest annual moves came in 2022 and 2023: Amortizatization of Intangibles climbed 8.37% in 2022, then grew 8.93% in 2023.
- Over 3 years, Amortizatization of Intangibles stood at $12385.0 in 2021, then grew by 8.79% to $13474.0 in 2022, then increased by 2.18% to $13768.0 in 2023.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $13768.0, $13474.0, and $13189.0 for Q1 2023, Q4 2022, and Q3 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Adial Pharmaceuticals | 29.02 Mn | 29.02 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 13,768.00 |
| Mar 31, 2023 | 13,768.00 |
| Dec 31, 2022 | 13,474.00 |
| Dec 31, 2022 | 13,474.00 |
| Sep 30, 2022 | 13,189.00 |
| Sep 30, 2022 | 13,189.00 |
| Jun 30, 2022 | 12,910.00 |
| Jun 30, 2022 | 12,910.00 |
| Mar 31, 2022 | 12,639.00 |
| Mar 31, 2022 | 12,639.00 |
| Dec 31, 2021 | 12,385.00 |
| Dec 31, 2021 | 12,385.00 |
| Sep 30, 2021 | 12,139.00 |
| Sep 30, 2021 | 12,139.00 |
| Jun 30, 2021 | 11,898.00 |
| Jun 30, 2021 | 11,898.00 |
| Mar 31, 2021 | 11,663.00 |
| Mar 31, 2021 | 11,663.00 |
| Dec 31, 2018 | 186,398.00 |
| Dec 31, 2018 | 186,398.00 |